Ambassador Advisors, LLC Genmab A/S Transaction History

Ambassador Advisors, LLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 12, 2022	SELL	$26.83 - $38.57 $80,999 - $116,442	-3,019 Reduced 21.01%	11,350 $368,000
Q1 2022 May 16, 2022	SELL	$30.95 - $39.68 $45,279 - $58,051	-1,463 Reduced 9.24%	14,369 $519,000
Q4 2021 Feb 14, 2022	SELL	$35.87 - $47.12 $403,824 - $530,476	-11,258 Reduced 41.56%	15,832 $626,000
Q3 2021 Nov 16, 2021	SELL	$41.55 - $48.72 $248,884 - $291,832	-5,990 Reduced 18.11%	27,090 $1.18 Million
Q2 2021 Aug 16, 2021	SELL	$32.88 - $44.57 $1.65 Million - $2.24 Million	-50,334 Reduced 60.34%	33,080 $1.35 Million
Q1 2021 May 13, 2021	BUY	$30.92 - $44.4 $2.58 Million - $3.7 Million	83,414 New	83,414 $2.74 Million
Q4 2020 Feb 17, 2021	SELL	$33.66 - $40.76 $3.27 Million - $3.95 Million	-97,012 Closed	0 $0
Q3 2020 Nov 13, 2020	SELL	$33.07 - $38.68 $4,067 - $4,757	-123 Reduced 0.13%	97,012 $3.55 Million
Q2 2020 Aug 13, 2020	BUY	$20.05 - $33.89 $1.95 Million - $3.29 Million	97,135 New	97,135 $3.29 Million

236

52.5M

10.2K

25.5K

Ticker GMAB
Exchange OTC
Sector Healthcare
Industry Biotechnology
Shares Outstandng 658,292,992
Market Cap $13.6B
Description
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphoc...

Get notified when there are updates to the investment portfolio of Ambassador Advisors, LLC, based on Form 13F filings with the SEC.

Stay updated on Ambassador Advisors, LLC with notifications on news.